CTLA-4 Blockade: Autoimmunity As Treatment

This publication has 24 references indexed in Scilit:

• Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
  Journal of Clinical Oncology, 2005
• Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
  The Journal of Experimental Medicine, 2001
• CD28/B7 SYSTEM OF T CELL COSTIMULATION
  Annual Review of Immunology, 1996
• Enhancement of Antitumor Immunity by CTLA-4 Blockade
  Science, 1996
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
  Science, 1995
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
  Immunity, 1995
• Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
  Immunity, 1994
• CTLA-4 can function as a negative regulator of T cell activation
  Immunity, 1994
• CTLA-4 is a second receptor for the B cell activation antigen B7.
  The Journal of Experimental Medicine, 1991
• Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway Determines the Outcome of T Cell Antigen Receptor Occupancy
  Annual Review of Immunology, 1989